RBRixing Bai

Rixing Bai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rixing Bai has a total of 198 co-authors. Here are the top co-authors by number of shared publications:

  • Zhongtao Zhang

    Department of General Surgery, Beijing Friendship Hospital, Capital Medical University; State Key Laboratory of Digestive Health; National Clinical Research Center for Digestive Diseases, Beijing, China

    4 shared publications
  • Jinghai Song

    Department of General Surgery, Beijing Hospital, National Center of Gerontology, Beijing, China

    3 shared publications
  • Nengwei Zhang

    Surgery Centre of Diabetes Mellitus, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, China

    3 shared publications
  • Yang Liu

    Department of General Surgery, Beijing Friendship Hospital, Capital Medical University & State Key Lab of Digestive Health & National Clinical Research Center for Digestive Diseases, Beijing, China

    3 shared publications
  • Mengyi Li

    Department of General Surgery, Beijing Friendship Hospital, Capital Medical University and National Clinical Research Center for Digestive Diseases, Beijing, China

    2 shared publications
  • Na Zeng

    National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China

    2 shared publications

Latest Publications

  • Characteristics and Outcomes of Patients With Imaging-Defined MASLD and Histological Steatosis Grade S0

    by Wen-Yue Liu, Li-You Lian, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Junping Shi, Wah-Kheong Chan, Jérôme Boursier, et al.

    INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease, and liver biopsy remains the gold standard for diagnosis. However, a subset of patients diagnosed with MASLD by imaging paradoxically exhibit steatosis grade S0 on liver biopsy, posing a diagnostic challenge. This study investigated the outcomes and causes of steatosis 0. METHODS: Steatosis 0 was defined as imaging-detected MASLD with a biopsy-defined steatosis grade S0. We used global cohorts to evaluate outcomes, histologic progression by paired biopsies, and possible causes. The cause analysis included MRI-proton density fat fraction (MRI-PDFF) for fat distribution, pathologist consistency testing, and comparison of serial biopsy sections. RESULTS: In a follow-up cohort of 3,273 biopsy individuals from 16 centers, 123 (3.8%) exhibited steatosis 0. Of these, 29.3% of them had advanced fibrosis (burnt-out MASLD) and demonstrated a risk of liver-related events, whereas those without advanced fibrosis had no such events. In the paired-biopsy cohort of 1,865 patients, 74 (4.0%) individuals initially showed steatosis grade S0; among them, 93.2% retained no or mild steatosis on follow-up biopsy. MRI-PDFF assessments in 42 MASLD patients revealed heterogeneous hepatic fat distribution, with some segments showing steatosis grade S0 despite elevated average liver fat. Interpathologist variability and discrepancies across consecutive biopsy sections contributed to misclassification of steatosis grade. DISCUSSION: Steatosis 0 represents a potential diagnostic gray zone in MASLD. It may be caused by burnt-out MASLD, uneven liver fat distribution, or variability in pathological assessment. Understanding the causes and implications of steatosis 0 is critical for diagnosis and management.

  • Open Access

    Effects of bariatric surgery on obesity associated gastroesophageal reflux disease: Insights from a systematic review and network meta-analysis

    by Ying Xing, Wen-Mao Yan, Ri-Xing Bai

    BACKGROUND Obesity is a global epidemic frequently associated with gastroesophageal reflux disease (GERD). Metabolic and bariatric surgery (MBS) is the most effective treatment for weight reduction in patients with obesity, with the most commonly performed procedures being sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and one-anastomosis gastric bypass (OAGB). Many recent studies focused on determining the best procedure for patients with obesity and GERD; however, results from these studies vary, and the optimal procedure remains uncertain. AIM To compare the effects of MBSs – SG, RYGB, and OAGB – and their combinations with antireflux procedures on weight loss and GERD outcomes. METHODS A systematic search was performed to identify randomized controlled trials evaluating MBS in patients with obesity and GERD. A network meta-analysis was conducted to estimate the relative effectiveness of different procedures on body mass index reduction, percent excess weight loss, GERD remission, GERD onset, postoperative proton pump inhibitor use, esophagitis, and complication rates. RESULTS Sixteen randomized controlled trials including SG, RYGB, OAGB and their combined procedures (i.e. , SGantiflux and OAGBantiflux), were analyzed. OAGBantiflux showed the highest body mass index reduction, and OAGB and RYGB had similar efficacies. In terms of percent excess weight loss, OAGB and RYGB ranked higher than other MBSs, whereas SGantiflux was the least effective. RYGB had the highest probability of GERD remission, followed by SG, SGantiflux, OAGB, and OAGBantiflux. SGantiflux showed the highest probability of the postoperative GERD onset, while SG was most likely to require postoperative proton pump inhibitor use and cause esophagitis. SGantiflux also demonstrated the highest complication rate, whereas OAGBantiflux was associated with the lowest, with OAGB, RYGB, and SG yielding intermediate rates in a descending order. CONCLUSION RYGB and OAGB were more effective than SG in patients with obesity and GERD, and addition of antireflux procedures to MBS did not improve GERD outcome.

  • Open Access

    Histological response and hepatic steatosis changes in nonalcoholic fatty liver disease after bariatric surgery: results from the Base-NAFLD Cohort

    by Mengyi Li, Na Zeng, Lu Yang, Yang Liu, Rixing Bai, Nengwei Zhang, Jinghai Song, Pin Zhang, Rong Hua, Di Cao, et al.

    Background: Distinguishing bariatric surgical effects on reversing nonalcoholic fatty liver disease (NAFLD) remain unclear. To assess discrepancies in histological response and changes in magnetic resonance imaging-proton density fat fraction (MRI-PDFF) after bariatric surgery. Methods: This prospective multicenter cohort included 138 NAFLD patients who underwent bariatric surgery and were followed up for 1 year. We obtained paired liver biopsy samples (n = 40), paired proteomic data (n = 23), and sequential MRI-PDFF at 3-, 6-, and 12-month (n = 80, 65, 52, respectively) follow-ups. Results: At 1 year, a ≥2-point improvement in NAFLD activity score (NAS) was observed in 80.0% of patients; nonalcoholic steatohepatitis (NASH) improved without fibrosis worsening in 42.1%; fibrosis improved without NASH worsening in 78.8% (95% confidence interval [CI]: 66.0–91.2, 26.8–58.2, and 63.0–91.3) (all P P <0.001). A ≥78.8% relative decline in MRI-PDFF within 1 year differentiated NAS improvement from non-NAS improvement (AUC, 0.912; 95% CI: 0.79–1.00). Compared to non-NASH remission, NASH remission was associated with significant pre- or postoperative regulation of protein expression levels. Conclusions: These findings can help evaluate the expected histological response, and aid in understanding the proteomic features resulting from the beneficial surgical effects on NAFLD and its advanced stages in patients with obesity.


  • Open Access

    Association of esophageal hiatus size with reflux esophagitis and type I hiatal hernia in patients with obesity

    by Zhong Qi, Xiao-Chen Shi, Wen-Mao Yan, Ri-Xing Bai

    BACKGROUND Chinese surgeons often rely on intraoperative exploration of the esophageal hiatus to determine the need for concurrent type I hiatal hernia (HH) repair during laparoscopic sleeve gastrectomy. However, no standardized criteria for the esophageal hiatus size or indications for exploration exist in China. AIM To investigate normal anatomical parameter ranges of the esophageal hiatus in patients with obesity. METHODS A total of 158 patients, aged 20-49 years, was analyzed from January 2020 to June 2024. The patients were classified into the no reflux esophagitis (RE) no HH group (HHG), RE group, and type I HHG. The transverse and sagittal diameters and cross-sectional area of the esophageal hiatus were measured using multiplanar reconstruction of the computed tomography images. RESULTS Body mass index was positively correlated with area and transverse and sagittal diameters of the esophageal hiatus (r = 0.72, 0.69, and 0.54, respectively; P < 0.01). In the no RE no HHG and RE group, the esophageal hiatus size in the subgroup with obesity was greater than that in the non-obesity subgroup (area: 326.15 ± 78 mm2 vs 208.12 ± 64.44 mm2, transverse diameters: 15.97 ± 2.06 mm vs 13.37 ± 1.99 mm, sagittal diameters: 15.7 ± 2.08 mm vs 11.73 ± 2.08 mm; P < 0.01). Patients with obesity showed no significant differences in esophageal hiatus size with or without RE or HH. CONCLUSION The esophageal hiatus size increased with body mass index and was larger in patients with obesity than in those without obesity.


  • Open Access

    Bariatric surgery for non-alcoholic fatty liver disease in individuals with obesity (Base-NAFLD): protocol of a prospective multicenter observational follow-up study

    by Luyang Wei, Mengyi Li, Na Zeng, Yang Liu, Rixing Bai, Nengwei Zhang, Jinghai Song, Pin Zhang, Qiyuan Yao, Zhenghan Yang, et al.

    Background: Bariatric surgery may be indicated in patients with nonalcoholic fatty liver disease (NAFLD) to achieve and maintain the degree of weight loss required to ensure therapeutic effects. However, bariatric surgery is still underrecognized in the treatment of NAFLD, including its inflammatory subtype, nonalcoholic steatohepatitis (NASH). Moreover, there is a lack of follow-up outcome data on different types of bariatric surgery in patients with NAFLD. This study aims to adequately assess the effect of bariatric surgery on NAFLD remission in obese patients. Methods: This prospective multicentre observational follow-up study will include 142 obese patients with NAFLD scheduled to undergo one of the following surgical procedures: sleeve gastrostomy, Roux-en-Y gastric bypass, and one anastomosis gastric bypass. The primary outcome is the complete remission rate of NAFLD one year postoperatively, which is defined by liver fat fraction < 5% on magnetic resonance imaging; the secondary outcomes includes (i) changes in NASH and liver fibrosis biopsy findings, (ii) changes in body weight and abdominal adipose weight, (iii) resolution of obesity-related comorbidities, and (iv) incidence of adverse events. A long-term follow-up related to this study will also be conducted. Discussion: This study will provide a necessary and preliminary foundation for the early identification and targeted treatment of patients with NAFLD who can be referred for bariatric surgery, as indicated for management of obesity and metabolic disease. Trial registration: Clinicaltrials.gov: NCT04366999. Registered 21 April 2020. (https://clinicaltrials.gov/ct2/show/NCT04366999).


  • The Choice of Gastric Bypass or Sleeve Gastrectomy for Patients Stratified by Diabetes Duration and Body Mass Index (BMI) level: Results from a National Registry and Meta-analysis

    by Mengyi Li, Na Zeng, Yang Liu, Wenmao Yan, Songhai Zhang, Liangping Wu, Shaozhuang Liu, Jun Wang, Xiangwen Zhao, Jianli Han, et al.

    Purpose To determine whether sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) should be the optimal choice in patients stratified by diabetes duration and body mass index (BMI) level. Methods Classification tree analysis was performed to identify the influential factors for surgical procedure selection in real setting. Meta-analyses stratified by influential factors were conducted to compare the complete diabetes remission rates between SG and RYGB. The cost-effectiveness analysis was performed when results from meta-analysis remain uncertain. Results Among 3198 bariatric procedures in China, 824 (73%) SGs and 191 (17%) RYGBs were performed in patients with T2DM. Diabetes duration with a cutoff value of 5 years and BMI level with 35.5 kg/m2 were identified as the influential factors. For patients with diabetes duration > 5 years, RYGB showed a significant higher complete diabetes remission rate than SG at 1 year: 0.52 (95% confidence interval (CI): 0.46–0.58) versus 0.36 (95% CI: 0.30–0.42). For patients with diabetes duration ≤ 5 years and BMI ≥ 35.5 kg/m2, there was no significant difference between 2 procedures: 0.57 (95% CI: 0.43–0.71) for SG versus 0.66 (95% CI: 0.62–0.70) for RYGB. The cost-effectiveness ratios of SG and RYGB were 244.58 and 276.97 dollars per QALY, respectively. Conclusions For patients with diabetes duration > 5 years, RYGB was the optimal choice with regard to achieving complete diabetes remission at 1 year after surgery. However, for patients with diabetes duration ≤ 5 years and BMI ≥ 35.5 kg/m2, SG appeared to provide a cost-effective choice. Graphical abstract


  • Open Access

    GSK3 inhibitor ameliorates steatosis through the modulation of mitochondrial dysfunction in hepatocytes of obese patients

    by Yaqiong Li, Yi Lin, Xueya Han, Weihong Li, Wenmao Yan, Yuejiao Ma, Xin Lu, Xiaowu Huang, Rixing Bai, Haiyan Zhang


  • Prediction of Long-Term Diabetes Remission After Metabolic Surgery in Obese East Asian Patients: a Comparison Between ABCD and IMS Scores

    by Masayuki Ohta, Yosuke Seki, Tetsuji Ohyama, Rixing Bai, Sang Hyun Kim, Takashi Oshiro, Tao Jiang, Akira Sasaki, Takeshi Naitoh, Tsuyoshi Yamaguchi, et al.

    Purpose Recently, more than 10 models have been developed to predict remission of type 2 diabetes mellitus (T2DM) after metabolic surgery. The ABCD score was compared to the individualized metabolic surgery (IMS) score in terms of prediction of T2DM remission, but which of the two scoring systems is better remains controversial. Methods Patient data from 463 obese East Asian patients who underwent laparoscopic Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), or SG with duodenojejunal bypass (SG-DJB) as a primary operation and were followed for at least 3 years were retrospectively collected from 24 institutions. The correlation between the ABCD and IMS scoring systems and the discrimination power of the models was evaluated. The cut-off point for the IMS stage of T2DM severity was also revised to adjust the scoring system to obese East Asian patients. Results The two scoring systems were significantly well correlated. The IMS scoring system showed significant differences in T2DM remission rates between the procedures in the moderate stage, but the ABCD score showed no significant differences in each category. The discrimination power of the IMS score was comparable to that of the ABCD score at both 3 and 5 years. The revised IMS scoring system showed that SG-DJB had significantly higher T2DM remission rates in the moderate stage at 5 years than RYGB or SG. Conclusion IMS score may be comparable to ABCD score to predict T2DM remission in obese East Asian patients. The revised IMS scoring system may also select candidates for SG or SG-DJB.


  • Analysis of Predictors of Type 2 Diabetes Mellitus Remission After Roux-en-Y Gastric Bypass in 101 Chinese Patients

    by Wenmao Yan, Rixing Bai, Youguo Li, Jun Xu, Zhiqiang Zhong, Ying Xing, Ming Yan, Yi Lin, Maomin Song

    To investigate prognostic factors for complete remission in type 2 diabetes mellitus (T2DM) patients who underwent gastric bypass (GBP) and to establish a prognostic model for risk stratification.